European Commission approves KALYDECO® for 1-month-old cystic fibrosis infants, treating specific CFTR gene mutations.
Vertex Pharmaceuticals announces the European Commission's approval of KALYDECO® for infants aged 1 month and older with cystic fibrosis, treating specific mutations in the CFTR gene. This approval is a milestone for the cystic fibrosis community, as early treatment can potentially slow disease progression. KALYDECO is the first and only EU-approved medicine for infants in this age group.
April 26, 2024
5 Articles